FindTrial
Sign In

Analysis of Overall Survival Rate and Cost-effectiveness of Different Integrated Traditional Chinese and Western Medicine Schemes in the Treatment of Primary Liver Cancer

Analysis of Overall Survival Rate and Cost-effectiveness of Different Integrated Traditional Chinese and Western Medicine Schemes in the Treatment of Primary Liver Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2100005396
Enrollment
Unknown
Registered
2021-12-11
Start date
2014-01-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary liver cancer

Interventions

group one:Dual therapy
group two:Triple therapy

Sponsors

Hongying Zhang
Lead Sponsor

Eligibility

Sex/Gender
All
Age
32 Years to 86 Years

Inclusion criteria

Inclusion criteria: (1) Age = 18 years; (2) No treatment before diagnosis; (3) Complete regular follow-up or examination; (4) Patients with Beijing medical insurance.

Exclusion criteria

Exclusion criteria: (1) Patients with metastatic liver cancer; (2) Pregnant or lactating women; (3) Patients with an estimated survival time of less than three months; (4) Patients with incomplete clinical information.

Design outcomes

Primary

MeasureTime frame
Overall survival rate;—

Secondary

MeasureTime frame
Cost-effectiveness;—

Countries

China

Contacts

Public ContactHongying Zhang
syzhy2018@163.com15901589079

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026